These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34685497)

  • 1. The Dual Role of Autophagy in Crizotinib-Treated ALK
    Espinos E; Lai R; Giuriato S
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
    Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
    Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
    Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
    Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells.
    Sorrentino D; Frentzel J; Mitou G; Blasco RB; Torossian A; Hoareau-Aveilla C; Pighi C; Farcé M; Meggetto F; Manenti S; Espinos E; Chiarle R; Giuriato S
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
    Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
    Prokoph N; Probst NA; Lee LC; Monahan JM; Matthews JD; Liang HC; Bahnsen K; Montes-Mojarro IA; Karaca-Atabay E; Sharma GG; Malik V; Larose H; Forde SD; Ducray SP; Lobello C; Wang Q; Luan SL; Pospíšilová Š; Gambacorti-Passerini C; Burke GAA; Pervez S; Attarbaschi A; Janíková A; Pacquement H; Landman-Parker J; Lambilliotte A; Schleiermacher G; Klapper W; Jauch R; Woessmann W; Vassal G; Kenner L; Merkel O; Mologni L; Chiarle R; Brugières L; Geoerger B; Barbieri I; Turner SD
    Blood; 2020 Oct; 136(14):1657-1669. PubMed ID: 32573700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
    Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
    Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.
    Ji C; Zhang L; Cheng Y; Patel R; Wu H; Zhang Y; Wang M; Ji S; Belani CP; Yang JM; Ren X
    Cancer Biol Ther; 2014 May; 15(5):570-7. PubMed ID: 24556908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Karaca Atabay E; Mecca C; Wang Q; Ambrogio C; Mota I; Prokoph N; Mura G; Martinengo C; Patrucco E; Leonardi G; Hossa J; Pich A; Mologni L; Gambacorti-Passerini C; Brugières L; Geoerger B; Turner SD; Voena C; Cheong TC; Chiarle R
    Blood; 2022 Feb; 139(5):717-731. PubMed ID: 34657149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.
    Petrazzuolo A; Perez-Lanzon M; Martins I; Liu P; Kepp O; Minard-Colin V; Maiuri MC; Kroemer G
    Cell Death Dis; 2021 Jul; 12(8):713. PubMed ID: 34272360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
    Ji J; Mitra A; Camidge DR; Riess JW
    Clin Lung Cancer; 2021 Nov; 22(6):e851-e855. PubMed ID: 34059475
    [No Abstract]   [Full Text] [Related]  

  • 16. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
    Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
    Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.